$1B+ in B2B pipeline generated through the myoProcess partnership · 2023–2025
Scalegroup finds the moment a company needs someone — and puts one specialist firm in front of it.
A round closes. A leader departs. An owner sells. Each of those opens work that has not been advertised yet. We watch the events rather than the job boards, and introduce each situation to a single specialist firm while the timing is still live.
The moments that open a need
Four from August 2026. Each one opens work before it reaches a job board.
- 1Vaderis Therapeutics — $152M Series B, global Phase 3 HEROIC study initiating.A Phase 3 start is the single largest clinical-operations hiring event a biotech has.
- 2Sidewinder Therapeutics — $137M Series B led by OrbiMed, IND filing targeted for end of 2026.IND filings pull regulatory, CMC and translational hires in ahead of the submission.
- 3Vima Therapeutics — Series A extended to $100M on 17 August.Extensions fund clinical development that was not staffed for at the original raise.
- 4InduPro — $77M oversubscribed Series B on 12 August, vaccine programme.Oversubscription usually means the plan grew between term sheet and close.
All four are public August 2026 announcements — funding, trial phase and regulatory filings. They are examples, not the list: the system tracks several thousand companies across four markets, and most of what it surfaces never gets published here.
A signal creates a need. We find it early and take it to one firm.
- Signal → needFunded rounds, leadership changes, liquidity events, new mandates — every one opens work that has not been posted yet. We watch the events, not the job boards.
- Need → one firmWe check fit on both sides, then make a single introduction — one firm per need, never a panel — while the timing is still live.
- Paid, and said upfrontFirms pay to receive these introductions. It is not a free referral list and it is not a panel. The commercials are explained in writing before anyone gets on a call.
- Where it worksAnywhere the trigger is publicly visible. That is the test, not the industry. Funding rounds and extensions. Leadership appointments and departures. Acquisitions, ownership changes and liquidity events. Regulatory filings, clearances and licence applications. Planning and development approvals. Insolvency and administration notices. Tender and contract awards. Life sciences, executive search and wealth advisory are simply the markets we have worked in most — if yours throws off signals like these, one call settles whether we can see them.
Results from the system we run on
Delivered through the myoProcess partnership, on the system every Scalegroup situation runs through.
- Hippocratic AI2 partners signed · 60 days
- Connect Group+$105K · 90 days
- Crawford Thomas Recruiting+$100K · 6 months
- Regent Peak Wealth Advisors6 qualified intros · 46 days
- Elate Staffing20 placements · 55 days
Partnership results since 2023, across executive search, life sciences and wealth advisory.
Deliberately small. The system behind it is not.
Scalegroup is a small desk running on myoProcess’s proprietary signal system.
- The signal engineScalegroup is a partner on myoProcess’s proprietary system — the same system behind $1B+ of B2B pipeline since 2023. Every situation we take to market runs through it.
- What gets trackedFunding rounds and extensions. Trial phase transitions, IND filings and regulatory clearances. Leadership departures and appointments. Ownership changes, liquidity events and succession. Facility expansions and new sites. Several thousand companies across four markets, checked continuously rather than researched on request.
- Systems, not headcountThe tracking, matching and outreach layer is built and maintained in-house. That is the reason a deliberately small operation covers this much ground without staffing a research floor to do it.
- One firm per situationA handful of partners in each market, and never the same need sent to five of them. Narrow on exclusivity, not on sector — the model stops working the moment a situation is shopped around, so it is not sold that way.
Mail from us does not always say Scalegroup
Outreach runs from more than one domain, so separate conversations stay in separate threads and a reply always lands on the right one. If you heard from any of these, it was us.
- Outreachscalegrouphub.com
- Outreachclientstrategyhub.com
- Outreachmarketstrategyhub.com
All three are ours, and every message from them carries a real name, my phone number and this website. If something claiming to be Scalegroup does not, it did not come from us — forward it to oscar@scalegroupresearch.com and I will look at it.